Ilyssa O Gordon1, Dominik Bettenworth2, Arne Bokemeyer2, Amitabh Srivastava3, Christophe Rosty4, Gert de Hertogh5, Marie E Robert6, Mark A Valasek7, Ren Mao8, Satya Kurada9, Noam Harpaz10, Paula Borralho11, Reetesh K Pai12, Rish K Pai13, Robert Odze14, Roger Feakins15, Claire E Parker16, Tran Nguyen16, Vipul Jairath17, Mark E Baker18, David H Bruining19, J G Fletcher20, Brian G Feagan17, Florian Rieder21. 1. Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 2. Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany. 3. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 4. Department of Clinical Pathology, The University of Melbourne, Parville, Victoria, Australia; Envoi Specialist Pathologists, Brisbane, Queensland, Australia; Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia. 5. Department of Pathology, University Hospital Leuven, Leuven, Belgium. 6. Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. 7. Department of Pathology, University of California San Diego, La Jolla, California. 8. Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 9. Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute; Cleveland Clinic Foundation, Cleveland, Ohio. 10. Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 11. Faculdade de Medicina da Universidade de Lisboa, Instituto de Anatomia Patológica, Lisbon, Portugal. 12. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 13. Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Arizona. 14. Pathology Department, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 15. Department of Cellular Pathology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom. 16. Robarts Clinical Trials, Inc, London, Ontario, Canada. 17. Robarts Clinical Trials, Inc, London, Ontario, Canada; Department of Medicine, Western University, London, Ontario, Canada; Department of Biostatistics and Epidemiology, Western University, London, Ontario, Canada. 18. Department of Diagnostic Radiology, Imaging Institute, Digestive Diseases and Surgery Institute, Cleveland, Ohio; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 19. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota. 20. Department of Radiology, Mayo Clinic, Rochester, Minnesota. 21. Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute; Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: riederf@ccf.org.
Abstract
BACKGROUND & AIMS: Stenosis is a common complication of Crohn's disease (CD) that has no effective medical therapy. Development of antifibrotic agents will require testing in randomized controlled trials. Computed tomography enterography- and magnetic resonance enterography-based technologies might be used to measure outcomes in these trials. These approaches have been validated in studies of patients with symptomatic strictures who underwent imaging evaluations followed by resection with histopathologic grading of the intestinal tissue for inflammation and/or fibrosis (the reference standard). Imaging findings have correlated with findings from quantitative or semiquantitative histologic evaluation of the degree of fibromuscular stenosis and/or inflammation on the resection specimen. However, it is not clear whether histologic findings are an accurate reference standard. We performed a systematic review of all published histologic scoring systems used to assess stenosing CD. METHODS: We performed a comprehensive search of Embase and MEDLINE of studies through March 13, 2019, that used a histologic scoring system to characterize small bowel CD and assessed inflammatory and fibrotic alterations within the same adult individual. All scores fitting the criteria were included in our analysis, independent of the presence of stricturing disease, as long as inflammation and fibrosis were evaluated separately but in the same scoring system. RESULTS: We observed substantial heterogeneity among the scoring systems, which were not derived from modern principles for evaluative index development. None had undergone formal validity or reliability testing. None of the existing indices had been constructed according to accepted methods for the development of evaluative indices. Basic knowledge regarding their operating properties were lacking. Specific indices for evaluating the important pathologic component of myofibroblast hypertrophy or hyperplasia have not been proposed. CONCLUSIONS: In a systematic review of publications, we found a lack of validated histopathologic scoring systems for assessment of fibromuscular stenosis. Data that describe the operating properties of existing cross-sectional imaging techniques for stenosing CD should be questioned. Development and validation of a histopathology index is an important research priority.
BACKGROUND & AIMS:Stenosis is a common complication of Crohn's disease (CD) that has no effective medical therapy. Development of antifibrotic agents will require testing in randomized controlled trials. Computed tomography enterography- and magnetic resonance enterography-based technologies might be used to measure outcomes in these trials. These approaches have been validated in studies of patients with symptomatic strictures who underwent imaging evaluations followed by resection with histopathologic grading of the intestinal tissue for inflammation and/or fibrosis (the reference standard). Imaging findings have correlated with findings from quantitative or semiquantitative histologic evaluation of the degree of fibromuscular stenosis and/or inflammation on the resection specimen. However, it is not clear whether histologic findings are an accurate reference standard. We performed a systematic review of all published histologic scoring systems used to assess stenosing CD. METHODS: We performed a comprehensive search of Embase and MEDLINE of studies through March 13, 2019, that used a histologic scoring system to characterize small bowel CD and assessed inflammatory and fibrotic alterations within the same adult individual. All scores fitting the criteria were included in our analysis, independent of the presence of stricturing disease, as long as inflammation and fibrosis were evaluated separately but in the same scoring system. RESULTS: We observed substantial heterogeneity among the scoring systems, which were not derived from modern principles for evaluative index development. None had undergone formal validity or reliability testing. None of the existing indices had been constructed according to accepted methods for the development of evaluative indices. Basic knowledge regarding their operating properties were lacking. Specific indices for evaluating the important pathologic component of myofibroblast hypertrophy or hyperplasia have not been proposed. CONCLUSIONS: In a systematic review of publications, we found a lack of validated histopathologic scoring systems for assessment of fibromuscular stenosis. Data that describe the operating properties of existing cross-sectional imaging techniques for stenosing CD should be questioned. Development and validation of a histopathology index is an important research priority.
Authors: Jeremy Adler; Darashana R Punglia; Jonathan R Dillman; Alexandros D Polydorides; Maneesh Dave; Mahmoud M Al-Hawary; Joel F Platt; Barbara J McKenna; Ellen M Zimmermann Journal: Inflamm Bowel Dis Date: 2011-06-24 Impact factor: 5.325
Authors: F Rieder; D Bettenworth; C Ma; C E Parker; L A Williamson; S A Nelson; G van Assche; A Di Sabatino; Y Bouhnik; R W Stidham; A Dignass; G Rogler; S A Taylor; J Stoker; J Rimola; M E Baker; J G Fletcher; J Panes; W J Sandborn; B G Feagan; V Jairath Journal: Aliment Pharmacol Ther Date: 2018-06-19 Impact factor: 8.171
Authors: Jonathan R Dillman; Ryan W Stidham; Peter D R Higgins; David S Moons; Laura A Johnson; Nahid R Keshavarzi; Jonathan M Rubin Journal: J Ultrasound Med Date: 2014-12 Impact factor: 2.153
Authors: Michael V Chiorean; Kumar Sandrasegaran; Romil Saxena; Dean D Maglinte; Attila Nakeeb; Cynthia S Johnson Journal: Am J Gastroenterol Date: 2007-09-26 Impact factor: 10.864
Authors: Sara El Ouali; Benjamin Click; Stefan D Holubar; Florian Rieder Journal: United European Gastroenterol J Date: 2020-01-14 Impact factor: 4.623
Authors: Calen A Steiner; Jeffrey A Berinstein; Jeremy Louissaint; Peter D R Higgins; Jason R Spence; Carol Shannon; Cathy Lu; Ryan W Stidham; Joel G Fletcher; David H Bruining; Brian G Feagan; Vipul Jairath; Mark E Baker; Dominik Bettenworth; Florian Rieder Journal: Clin Gastroenterol Hepatol Date: 2021-06-02 Impact factor: 11.382
Authors: Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Jiannan Li; Noam Harpaz; Paula Borralho; Reetesh K Pai; Robert Odze; Roger Feakins; Claire E Parker; Leonardo Guizzetti; Tran Nguyen; Lisa M Shackelton; William J Sandborn; Vipul Jairath; Mark Baker; David Bruining; Joel G Fletcher; Brian G Feagan; Rish K Pai; Florian Rieder Journal: Gut Date: 2021-05-05 Impact factor: 23.059
Authors: Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder Journal: Immunol Rev Date: 2021-05-16 Impact factor: 10.983
Authors: Ren Mao; Genevieve Doyon; Ilyssa O Gordon; Jiannan Li; Sinan Lin; Jie Wang; Thi Hong Nga Le; Michael Elias; Satya Kurada; Brian Southern; Mitchell Olman; Minhu Chen; Shuai Zhao; Dina Dejanovic; Jyotsna Chandra; Pranab K Mukherjee; Gail West; David R Van Wagoner; Claudio Fiocchi; Florian Rieder Journal: Gut Date: 2021-01-19 Impact factor: 31.793
Authors: Arne Bokemeyer; Phil Robin Tepasse; Lena Quill; Philipp Lenz; Emile Rijcken; Michael Vieth; Nik Ding; Steffi Ketelhut; Florian Rieder; Björn Kemper; Dominik Bettenworth Journal: Sci Rep Date: 2019-12-18 Impact factor: 4.379
Authors: Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder Journal: Expert Rev Gastroenterol Hepatol Date: 2020-12-28 Impact factor: 3.869